FireCyte Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

FireCyte Therapeutics is a private, preclinical-stage biotech founded in 2018 and based in San Diego, CA. The company is engineering first-in-class fusion protein therapeutics designed to simultaneously engage SORT1 and DCC receptors to modulate neuroinflammation and provide direct neuroprotection. Its lead program targets retinal disorders like glaucoma, aiming to address a critical unmet need where current standard of care fails to halt disease progression, with a long-term vision to expand into other neurodegenerative conditions.

OphthalmologyNeuroscience

Technology Platform

Engineered fusion proteins derived from IGFBPL1 designed to simultaneously engage SORT1 and DCC receptors to modulate microglial activity (anti-inflammatory) and provide direct neuroprotection.

Opportunities

The primary opportunity is addressing the large unmet need in glaucoma, where 25-33% of patients progress despite standard care, and specifically in normotensive glaucoma which lacks effective treatments.

Success in the eye could also validate the platform for expansion into larger neurodegenerative disease markets like Alzheimer's or Parkinson's.

Risk Factors

Key risks include the high failure rate of preclinical/clinical development for novel CNS therapeutics, the unproven mechanism of its dual-target fusion protein in humans, and dependence on securing sufficient venture funding in a challenging financial environment to advance its programs.

Competitive Landscape

The neuroprotection space in ophthalmology is active but has seen many failures, with no approved disease-modifying therapies for glaucoma beyond IOP-lowering. FireCyte's differentiated dual-mechanism approach (anti-inflammatory + direct neuroprotection) could position it uniquely if successful, but it faces potential competition from other biotechs and large pharma exploring similar pathways.

More companies in Neuroscience & CNS →More companies in United States →